ASCO 2014

Viewing 1-20 of 35 articles

#ASCO14 - Poster: Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

#ASCO14 - Poster: Activity of abiraterone acetate in metastatic castration-resistant prostate cancer patients previously treated with ketoconazole: A prospective phase II study from the Prostate Cancer Clinical Trials Consortium

#ASCO14 - The site of visceral metastases to predict overall survival in castration-resistant prostate cancer (CRPC) patients: A meta-analysis of five phase III trials - Session Highlights

#ASCO14 - Final results of EORTC intergroup randomized phase III trial comparing immediate vs deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder - Session Highlights

#ASCO14 - Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011) - Session Highlights

#ASCO14 - Poster: Establishing a neo-adjuvant platform for developing targeted agents: Androgen deprivation therapy prior to prostatectomy for patients with intermediate- and high-risk prostate cancer

#ASCO14 - Poster: PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action

#ASCO14 - Poster: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data

#ASCO14 - Poster: Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel

#ASCO14 - Poster: Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo

#ASCO14 - Poster: Enzalutamide monotherapy: 1-year extended follow-up of a Phase 2 study in hormone-naive prostate cancer patients

#ASCO14 - Poster: Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel

#ASCO14 - Poster: Predicting response to abiraterone acetate: mRNA biomarker analysis of study COU-AA-302

#ASCO14 - Poster: A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer–the SPARTAN trial

#ASCO14 - Poster: Final analysis of a large, open-label global early access protocol with abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

#ASCO14 - Poster: Symptomatic skeletal events in patients with advanced prostate cancer: Results from a phase 3 trial of denosumab for the prevention of skeletal-related events

#ASCO14 - Poster: Patient-reported quality of life analysis of radium-223 dichloride evaluating pain relief from the phase 3 ALSYMPCA study

#ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide...

#ASCO14 - Poster: 15-year survival outcomes following primary androgen deprivation therapy for localized prostate cancer

#ASCO14 - Poster: Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED

1
2